1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 技術別スニペット
3.2. アプリケーション別スニペット
3.3. エンドユーザー別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性感染症および非感染症の有病率の増加
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 医療インフラの欠如
4.1.2.2. 人々の認識不足
4.1.2.3. 熟練した専門家の不足
4.1.2.4. 厳しい規制要件
4.1.3. ビジネスチャンス
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. 技術別
6.1. はじめに
6.1.1. 市場規模分析と前年比成長率分析（%）, 技術別
6.1.2. 市場魅力度指数、技術別
6.2. ラテラルフローアッセイ*市場
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 凝集測定法
6.4. フロースルー
6.5. ディップスティック法（固相法）
6.6. マイクロ流体チップ
6.7. その他
7. 用途別
7.1. 導入
7.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
7.1.2. 市場魅力度指数：用途別
7.2. グルコースモニタリング*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 循環代謝検査
7.4. 感染症検査
7.5. 乱用薬物検査
7.6. その他
8. エンドユーザー別
8.1. 導入
8.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
8.1.2. 市場魅力度指数、エンドユーザー別
8.2. 病院と診療所
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 診断センター
8.4. 在宅医療
8.5. その他
9. 競争環境
9.1. 競争シナリオ
9.2. 市場ポジショニング／シェア分析
9.3. M&A分析
10. 企業プロフィール
10.1. Merck KGaA*
10.1.1. 会社概要
10.1.2. 製品ポートフォリオと内容
10.1.3. 財務概要
10.1.4. 主な展開
10.2. Thermo Fisher Scientific Inc.
10.3. Abbott
10.4. Beckman Coulter Inc.
10.5. Bio-Rad Laboratories Inc.
10.6. Creative Diagnostics
10.7. Becton Dickinson and Company
10.8. Goldsite Diagnostics Inc.
10.9. InTec Products Inc.
10.10. Protia Inc. (*リストは除く)
11. 付録
11.1. 会社概要とサービス
11.2. お問い合わせ

Report Overview
The Asia-Pacific rapid diagnostic testing kits market reached US$ 4.30 billion in 2023 and is expected to reach US$ 8.12 billion by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.

A rapid diagnostic test (RDT) is a medical diagnostic test that is quick and easy to perform. RDTs are suitable for preliminary or emergency medical screening and for use in medical facilities with limited resources. They also allow point-of-care testing in primary care for things that formerly only a laboratory test could measure. They provide same-day results within two hours, typically in approximately 20 minutes.
Rapid diagnostics are based on the same immunochromatographic technology as standard home pregnancy tests. Most rapid diagnostics use blood from finger pricks (although venous blood works). In general, rapid diagnostics offer comparable sensitivity to smear microscopy with much less interobserver variability. Their principle is to capture antibodies on a solid surface where complementary antigens are attached. Different technologies are used, like immune chromatography, lateral flow tests, and cassettes. There is a control line that can confirm the correct liquid migration.

Market Dynamics: Drivers
Increasing prevalence of chronic infectious and non-infectious diseases
The rising prevalence of various medical conditions propels the market growth. For instance, according to the estimates posted by unaids.org in 2023, there are 25,00,000 adults and children living with HIV in India. There are 68,000 adults and children newly infected in the previously mentioned statistics. There are 36,000 deaths due to AIDS in 2023. The prevalence rate is 0.3. Moreover, according to the estimates posted by unaids.org in 2023, there are 2,90,000 adults and children living with HIV in Pakistan. There are 11,000 deaths in Pakistan due to AIDS.
And the anti-retroviral therapy coverage in Pakistan is 99.2%. The HIV prevalence percentage in Pakistan is 2%. The anti-retroviral therapy coverage in India is 70%. For instance, according to the estimates posted by unaids.org in 2023, there are 76,000 adults and children living with HIV in Cambodia. The anti-retroviral therapy coverage in Cambodia is 100%. There are 1,200 adults and children newly infected in the previously mentioned statistics.

Restraints
Factors such as lack of healthcare infrastructure, lack of awareness among people, shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.

Market Segment Analysis
The Asia Pacific rapid diagnostic testing kits market is segmented based on technology, application, and end-user.
The segment infectious disease testing accounted for approximately 56.6% of the Asia Pacific rapid diagnostic testing kits market share
The infectious disease testing segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research works would drive this market.
For instance, in June 2023, to improve the offering in the in vitro diagnostics (IVD) field, Bengaluru-based startup GenWorks announced the launch of its IVD tests including rapid card test kits for dengue and malaria. The use of IVD products for dengue and malaria is aimed at preventing, diagnosing, curing, and treating seasonal epidemics and mitigating their impact.
Moreover, according to an article published by the Times of India in June 2024, India saw a striking 122% surge in dengue cases and a 16% increase in those of malaria in a year, underlining a persistent rise in vector-borne diseases, which pose a growing threat. The economic survey report underscored the continued increase in reported cases of infectious diseases like leprosy and TB.

Market Segmentation
By Technology
Lateral Flow Assay
Agglutination Assay
Flow-through
Dipstick Assay (Solid-phase)
Microfluidic chips
Others
By Application
Glucose Monitoring
Cardiometabolic Testing
Infectious Disease Testing
Drugs of Abuse Testing
Others
By End-User
Hospitals and Clinics
Diagnostic Centers
Homecare
Others
Market

Competitive Landscape
The major players in the Asia Pacific rapid diagnostic testing kits market include Merck KGaA, Thermo Fisher Scientific Inc., Abbott, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Creative Diagnostics, Becton, Dickinson and Company, Goldsite Diagnostics Inc., InTec Products Inc., Protia Inc. among others.

Key Developments
In February 2023, Pune-based Mylab Discovery Solutions launched three new rapid kits for the early and fast detection of sexually transmitted infections (STIs) such as Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Syphilis. These infections pose a major health challenge as World Health Organisation (WHO) estimates say that the daily caseload of STIs is set to reach 1 million per day globally.
In July 2023, in a bid to reduce the life-threatening complications and consequences associated with tuberculosis (TB), EMPE Diagnostics launched its one-of-its-kind test kit mfloDx™ MDR-TB at Telangana Lifesciences office, in Hyderabad.

Why Purchase the Report?
To visualize the Asia Pacific rapid diagnostic testing kits
Market Segmentation based on technology, application, and end-user as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of Asia Pacific rapid diagnostic testing kits market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific rapid diagnostic testing kits market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Technology
3.2. Snippet by Application
3.3. Snippet by End-User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Chronic Infectious and Non-Infectious Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Healthcare Infrastructure
4.1.2.2. Lack of Awareness Among People
4.1.2.3. Shortage of Skilled Professionals
4.1.2.4. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Technology
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Lateral Flow Assay*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Agglutination Assay
6.4. Flow-through
6.5. Dipstick Assay (Solid-phase)
6.6. Microfluidic chips
6.7. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Glucose Monitoring*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiometabolic Testing
7.4. Infectious Disease Testing
7.5. Drugs of Abuse Testing
7.6. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals and Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Centers
8.4. Homecare
8.5. Others
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Merck KGaA*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Thermo Fisher Scientific Inc.
10.3. Abbott
10.4. Beckman Coulter Inc.
10.5. Bio-Rad Laboratories Inc.
10.6. Creative Diagnostics
10.7. Becton Dickinson and Company
10.8. Goldsite Diagnostics Inc.
10.9. InTec Products Inc.
10.10. Protia Inc. (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us

❖ 世界の迅速診断検査キット市場に関するよくある質問(FAQ) ❖

・迅速診断検査キットの世界市場規模は？
→DataM Intelligence社は2023年の迅速診断検査キットの世界市場規模を43.0億米ドルと推定しています。

・迅速診断検査キットの世界市場予測は？
→DataM Intelligence社は2031年の迅速診断検査キットの世界市場規模を81.2億米ドルと予測しています。

・迅速診断検査キット市場の成長率は？
→DataM Intelligence社は迅速診断検査キットの世界市場が2024年～2031年に年平均8.4%成長すると予測しています。

・世界の迅速診断検査キット市場における主要企業は？
→DataM Intelligence社は「Merck KGaA、Thermo Fisher Scientific Inc.、Abbott、Beckman Coulter Inc.、Bio-Rad Laboratories Inc.、Creative Diagnostics、Becton, Dickinson and Company、Goldsite Diagnostics Inc.、InTec Products Inc.、Protia Inc.など ...」をグローバル迅速診断検査キット市場の主要企業として認識しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。